Bio-Rad Laboratories, Inc. (BIO.B)
NYSE: BIO.B · Real-Time Price · USD
339.07
0.00 (0.00%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Bio-Rad Laboratories Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 517 | 529.8 | 488.1 | 403.8 | 434.22 | 470.78 |
Short-Term Investments | 1,102 | 1,011 | 1,176 | 1,209 | 1,362 | 404.7 |
Cash & Short-Term Investments | 1,619 | 1,541 | 1,665 | 1,613 | 1,796 | 875.48 |
Cash Growth | 17.81% | -7.44% | 3.21% | -10.22% | 105.17% | -12.16% |
Accounts Receivable | 441.8 | 460.6 | 452.5 | 489 | 494.65 | 423.54 |
Inventory | 780.6 | 740.7 | 760 | 780.5 | 719.32 | 572.24 |
Other Current Assets | 179.6 | 164.2 | 153.3 | 166.1 | 147.78 | 119.23 |
Total Current Assets | 3,021 | 2,906 | 3,030 | 3,048 | 3,158 | 1,990 |
Net Property, Plant & Equipment | 671.9 | 709.9 | 688.6 | 723.7 | 679.56 | 716.44 |
Other Intangible Assets | 160 | 174.3 | 293.6 | 320.5 | 332.15 | 253.94 |
Goodwill | 574.3 | 579.8 | 410.5 | 413.6 | 406.49 | 347.34 |
Long-Term Investments | 5,724 | 6,104 | 4,839 | 7,698 | 8,831 | 14,387 |
Other Long-Term Assets | 101.7 | 102.7 | 101.9 | 94.9 | 94.6 | 104.19 |
Total Assets | 10,252 | 10,577 | 9,364 | 12,299 | 13,502 | 17,799 |
Accounts Payable | 143.5 | 129 | 122.3 | 144.6 | 135.04 | 141.94 |
Accrued Expenses | 150.5 | 172.3 | 124.2 | 139.9 | 194.79 | 276.99 |
Current Portion of Long-Term Debt | 400.7 | 1.3 | 1.2 | 0.5 | 0.47 | 0.49 |
Current Portion of Leases | 33.6 | 36.1 | 41.7 | 40.4 | 36.34 | 36.44 |
Unearned Revenue | - | - | - | - | - | 50.85 |
Other Current Liabilities | 233 | 178.3 | 178.4 | 197.4 | 202.08 | 174.24 |
Total Current Liabilities | 961.3 | 517 | 467.8 | 522.8 | 568.71 | 680.94 |
Long-Term Debt | 803 | 1,202 | 1,200 | 1,199 | 1,198 | 10.51 |
Long-Term Leases | 133.1 | 145.7 | 131.4 | 165.5 | 153.6 | 175.94 |
Other Long-Term Liabilities | 1,181 | 1,259 | 995.2 | 1,671 | 1,966 | 3,247 |
Total Long-Term Liabilities | 2,117 | 2,606 | 2,327 | 3,035 | 3,318 | 3,433 |
Total Liabilities | 3,078 | 3,123 | 2,795 | 3,558 | 3,886 | 4,114 |
Common Stock | - | - | - | - | 0 | 0 |
Treasury Stock | -1,078 | -1,010 | -772.1 | -632.5 | -263.59 | -106.29 |
Additional Paid-in Capital | 502.9 | 476 | 463.2 | 449.1 | 447.45 | 441.73 |
Accumulated Other Comprehensive Income | -271.3 | -189.1 | -538.2 | -336 | -466.82 | -175.55 |
Retained Earnings | 8,021 | 8,176 | 7,416 | 9,261 | 9,898 | 13,525 |
Shareholders' Equity | 7,174 | 7,454 | 6,569 | 8,741 | 9,615 | 13,685 |
Total Liabilities & Equity | 10,252 | 10,577 | 9,364 | 12,299 | 13,502 | 17,799 |
Total Debt | 1,370 | 1,385 | 1,375 | 1,406 | 1,388 | 223.38 |
Net Cash (Debt) | 248.1 | 155.9 | 289.8 | 207.2 | 408.12 | 652.1 |
Net Cash Growth | - | -46.20% | 39.87% | -49.23% | -37.41% | -15.42% |
Net Cash Per Share | 9.21 | 5.71 | 10.27 | 7.09 | 13.70 | 21.59 |
Book Value | 7,174 | 7,454 | 6,569 | 8,741 | 9,615 | 13,685 |
Book Value Per Share | 266.42 | 273.22 | 232.84 | 299.26 | 322.82 | 453.03 |
Tangible Book Value | 6,440 | 6,700 | 5,865 | 8,007 | 8,877 | 13,084 |
Tangible Book Value Per Share | 239.15 | 245.57 | 207.88 | 274.13 | 298.02 | 433.13 |